81 results about "Peptide antigen" patented technology

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The embodiment of the invention provides a polypeptide antigen as well as a preparation method and application thereof. The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg, and the amino acid sequence of the polypeptide antigen is as shown in the specification. The polypeptide antigen has high conformational stability, by arranging a diphenyl cyclooctyne group (DBCO) on a side chain of a Lys residue in the polypeptide antigen and through group modification, the activity of carrying out a click chemical reaction with an endogenous or exogenous azide of a biological system is provided, and the circulation half-life period of polypeptide in a body is remarkably prolonged; through an annular structure and group modification, the polypeptide antigen can effectively target and act on T cells, and the treatment efficiency is improved.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

A method for measuring kinetics of Ca2+ flux in differentially responding T cells that form monolayer on the glass surface in response to antigenic peptides or live target cells comprising: immobilizing T cells labeled with Ca2+ sensitive fluorophore on the glass bottom of a well, covered with capturing antibody or a capturing protein that bind to non-stimulatory T-cell surface receptor; adding to the well a single or multiple peptide epitopes that binds to the cell surface MHC molecules to be presented for recognition by cognate T cells; the stimulatory signal could also be delivered by live target cells that display peptide epitope(s); wherein the recognition of stimulatory of pMHC by the peptide specific T cells leads to increase of intracellular Ca2+ level and fluorescence intensity in the responding T cells, which is then identified after the subtracting fluorescence intensity for every T cell before and after the addition of the peptide antigens; scoring each responding T cell into a category according to three categories including: a rapid and sustained T-cell response, an oscillatory response, or a delayed and oscillatory response; and measuring changes in number of an individual T cells with increased intracellular fluorescence as function of time provides the kinetic curve of the TCR-mediated Ca2+ signaling.

A method for enhancing the immunogenicity of protein / peptide antigens, which comprises conjugating the protein / peptide antigen with a sugar to form a glyco-protein / peptide antigen conjugate, whose immunogenicity is enhanced compared to the unconjugated protein / peptide antigen. Specifically, it involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof, with a polysaccharide, especially the capsular polysaccharide of Streptococcus pneumoniae. The conjugate with enhanced immunogenicity can be used for preventing or treating diseases caused by pathogens, especially diseases caused by coronaviruses.

The invention relates to antibodies against extracellular epitopes of human Transient Receptor Potential Vanilloid 6 (TRPV6) channel protein, in particular antibodies which modulate TRPV6 channel activity on the plasma membrane and thereby trigger apoptosis of cancer cells expressing TRPV6. The invention relates also to the use of said antibodies for the diagnosis, prognosis and treatment of diseases involving TRPV6 channels, in particular diseases associated with TRPV6-expression such as cancers. The invention further relates to peptide antigens from human TRPV6 protein useful for the production of said antibodies.

The invention belongs to the technical field of medicines, and particularly relates to a milk acylation modified Myh6 protein and application thereof. The antigen polypeptide for identifying the heart failure marker has an amino acid sequence as shown in SEQ ID NO: 1, lysine located at the 9th site is subjected to milk acylation modification, and the heart failure marker is milk acylation modified Myh6 protein; the milk acylation modified Myh6 protein is a lysine milk acylation modified protein (Myh6-K1897) which is located at the 1897 site of a wild type Myh6 protein. The Myh6-K1897 can be used as a marker for identifying heart failure as a target spot, is a set of novel and perfect protein milk acylation molecular regulation and control system, can judge the interaction between Myh6 and Tin, and is used for treating the core and key of heart failure. The research provides a new and powerful treatment strategy for the treatment of human heart failure diseases.

The invention discloses a polypeptide-based avian reticuloendotheliosis virus indirect ELISA antibody detection method, and belongs to the technical field of biology. According to the kit, potential epitopes of REV gp90 protein are systematically screened to obtain three sections of specific polypeptide antigens for detecting the avian reticuloendotheliosis virus antibody, and a mixed product of the three sections of specific polypeptide antigens is used as a coating antigen to develop the indirect ELISA antibody detection kit for the avian reticuloendotheliosis virus. On the basis of the indirect ELISA antibody detection kit, the avian reticuloendotheliosis virus antibody detection method established by optimizing the coating concentration, the sealing condition, the serum incubation time and the like has the advantages of strong specificity, high sensitivity, good repeatability and convenience in operation; the kit can effectively and rapidly diagnose epidemic diseases caused by the avian reticuloendotheliosis virus, and is beneficial to popularization and application.

The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.

The embodiment of the present application provides a kind of polypeptide antigen and its preparation method and application.The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg.The polypeptide antigen in the present application has strong conformational stability, by setting up diphenyl cyclooctyne group (DBCO) on the side chain of Lys residue in polypeptide antigen, by group modification, provide the activity of click chemistry reaction with endogenous or exogenous azide compound in biological system, significantly prolong the circulating half-life of polypeptide in vivo;Through cyclic structure and group modification, the polypeptide antigen can effectively target and act on T cell, improve treatment efficiency.

Engineered filamentous bacteriophage particle are provided, and DNA extracted from such phage particles, including: (a) a filamentous bacteriophage capsid comprising a peptide antigen displayed on a surface of the capsid; and (b) a single stranded DNA molecule (ssDNA) encapsulated within the capsid, wherein the single stranded DNA molecule; wherein (i) the ssDNA comprises at least 12% unmethylated CG dinucleotides; (ii) the ssDNA comprises sequences encoding bacteriophage (A) fl-ori, (B) fl-term, and (C) packaging signal; and (iii) the ssDNA comprises less than 50% bacteriophage ssDNA.

The invention relates to the technical field of biological medicines, and provides an EGFR L858R mutation specific long peptide vaccine and application thereof. The long peptide vaccine provided by the invention comprises dendritic cells which are loaded by a long peptide antigen modified by a cell penetrating peptide and are induced to be mature. According to the invention, a long peptide sequence with good immunogenicity and affinity is screened out, and specific T cell immune response can be effectively induced. And the long peptide antigen is modified by adopting cell penetrating peptide (CPPs), so that efficient loading and delivery of the long peptide antigen in dendritic cells (DC) are realized. According to the vaccine, the presentation capacity of antigens is remarkably enhanced, CD8 + T cells can be effectively activated, the expression level of IFN-gamma is remarkably improved, and strong specific immune response is induced. In addition, when the vaccine is used in combination with a PD-1 antibody, the tumor immune microenvironment is further improved, and the immune activation effect is enhanced.

To provide antigen-binding proteins (ABPs) for use to discover and identify tumor-associated HLA-peptide complexes with highly positive predictive value, and for use in TCR-based immunotherapies targeting such complexes.SOLUTION: The disclosure provides an ABP that binds specifically to an HLA-peptide antigen comprising an HLA-restricted peptide forming a complex with an HLA Class I molecule, where the HLA-restricted peptide is located in the peptide binding groove of an α1 / α2 heterodimer portion of the HLA Class I molecule, where the HLA Class I molecule and the HLA-restricted peptide each have a specific amino acid sequence, and where the ABP comprises a T cell receptor (TCR) or antigen-binding fragment thereof.SELECTED DRAWING: Figure 12

A method for enhancing the immunogenicity of a protein / peptide antigen is provided, wherein the protein / peptide antigen forms a fusion protein with an Fc fragment, preferably with receptor-binding / complement-binding enhanced Fc fragment, and further forms a fusion protein glycoconjugate with a glycosyl group. In the preferred embodiment, the Fc fragment, due to alterations in its amino acid sequence and / or glycosylation, has an enhanced binding capacity to Fc receptors and / or complement protein C1q compared to its native form. Such vaccines can maintain long-term humoral and cellular immune responses, exhibiting higher cellular immune responses and producing higher titers of neutralizing antibodies in immunized animals. Using the SARS-CoV-2 RBD region as the antigen in an immunizing composition, it is formed into a fusion protein with an Fc region that has undergone amino acid sequence and fucose alteration, and further forms a fusion protein glycoconjugate with pneumococcal polysaccharide, for the prevention of SARS-CoV-2 infection-related diseases.

It has been established that the efficacy of mRNA vaccines encoding one or more peptide antigens for expression in a host cell can be enhanced by the addition of one or more mRNA sequences encoding peptide adjuvant(s) for expression of the adjuvant in the same host cell. Compositions of vaccines including mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are described. The peptide antigen(s) and peptide adjuvant(s) can be encoded on the same or different mRNA molecule. In some forms, the vaccines include a single mRNA molecule encoding an antigen and an adjuvant, for expression in the same host cell. Nanoparticles encapsulating the mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are provided for administration to a subject in vivo. Methods of vaccinating a subject including administering to the subject a composition including mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are also described.

The present disclosure provides a broad-spectrum peptide antigen of SARS-COV-2, a specific neutralizing antibody and use thereof. A broad-spectrum peptide antigen of SARS-COV-2, with an amino acid sequence comprising SEQ ID NO: 1, reacts with human SARS-COV-2 positive serum, and can specifically bind to a novel coronavirus antibody. Based on the peptide sequence of the present disclosure, a fusion protein with broad-spectrum triple tandem peptides of SARS-COV-2 is prepared using PCR, prokaryotic expression, and protein purification technology which simulates the trimeric mode of SARS-COV-2 S protein in its natural state. The fusion protein is used as an antigen to immunize mice, and can produce a specific anti-SARS-CoV-2 neutralizing antibody. The neutralizing antibody may be promising in anti-infective treatment, vaccine development and detection kit development for SARS-COV-2.

Disclosed herein are methods, systems, computer-implemented methods, and computer-accessible media for modifying and / or redesigning peptide-centric chimeric antigen receptors (PC-CARs) against novel peptide antigens.

Provided is an immunostimulatory preparation which is a protein obtained by fusing a bacteria-derived heat shock protein (HSP: heat shock protein) and a viral peptide antigen, and enables induction of a highly diverse immunoglobulin by simultaneously stimulating nasal, respiratory, and oral administration. Provided are a feed, a feed additive, and an environmental symbiotic preparation for livestock, or a cosmetic, a food, and a quasi-pharmaceutical product for humans, which enable symbiosis with an environmental microorganism containing the immunostimulatory preparation. Provided are a preparation, a cosmetic for humans, a food, and a quasi-pharmaceutical product that enable symbiosis with environmental microorganisms utilizing livestock-derived IgA, IgG, and IgY among the immunoglobulins.

The application belongs to the technical field of biotechnology, and particularly discloses a synthetic peptide antigen of porcine circovirus type 2 Cap protein, a polyclonal antibody and application thereof. In order to solve the technical defects of low specificity and inaccurate detection of the amino acid sequence of the synthetic peptide antigen in the prior art, the application provides a synthetic peptide antigen of PCV2 Cap protein, a polyclonal antibody and application thereof. The application obtains an amino acid sequence of an antigen peptide by performing antigen peptide prediction on PCV2 Cap protein, and the applicant synthesizes the antigen peptide by using an Fmoc solid phase method, and immunizes a New Zealand white rabbit with the obtained antigen peptide to prepare a polyclonal antibody of Cap protein, the antibody can effectively react with a transiently expressed Cap protein and a Cap protein in PCV2b-infected PK15 cells, and provides a powerful tool for detection and biological function research of the PCV2 Cap protein.

An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and / or one or more CD4+ helper T cell recognition epitopes, which is / are derived from the antigen. The antigen-loaded nanogel is administered at least one day prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from the group consisting of PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG wherein E1 is the N-terminal extension, E2 is the C-terminal extension, A is a peptide antigen, H is a hydrophobic block wherein one or more drug molecules (D) are optionally attached to each H either directly or via a suitable linker X1; u is a linker, [] represents a group being optional, and-represents that two adjacent groups are attached to each other directly via a covalent bond or indirectly via a suitable linker X. The vaccine can be used to treat or prevent cancer, autoimmune disease, allergy or infectious disease.

An immunotherapeutic composition comprising a subject-derived peripheral blood mononuclear cell (PBMC) and at least one recombinant adenoviral subtype 5 (Ad5) comprising a deletion in the E1 gene region, a deletion in the E2b gene region and a nucleic acid sequence encoding a peptide antigen wherein the PBMC is exposed ex vivo to the at least one Ad5 vector is contemplated. Advantageously, the same PBMC composition can also be used to prepare modified NK cells, and in particular the modified NKs include CIML NK cells, CENK cells and mCENK cells.

The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.